Understanding patient perspectives in the management of their muscle-invasive bladder cancer

IF 4.4 2区 医学 Q1 UROLOGY & NEPHROLOGY BJU International Pub Date : 2025-03-06 DOI:10.1111/bju.16695
Deepro Chowdhury, Andrea B. Apolo, Di Maria Jiang, Eila C. Skinner, Stephanie Chisolm, Rick Bangs, Manjula Maganti, Gary D. Steinberg, Matthew Kaag, Jason A. Efstathiou, Srikala S. Sridhar
{"title":"Understanding patient perspectives in the management of their muscle-invasive bladder cancer","authors":"Deepro Chowdhury,&nbsp;Andrea B. Apolo,&nbsp;Di Maria Jiang,&nbsp;Eila C. Skinner,&nbsp;Stephanie Chisolm,&nbsp;Rick Bangs,&nbsp;Manjula Maganti,&nbsp;Gary D. Steinberg,&nbsp;Matthew Kaag,&nbsp;Jason A. Efstathiou,&nbsp;Srikala S. Sridhar","doi":"10.1111/bju.16695","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To evaluate the impact of advocacy efforts by organisations such as the Bladder Cancer Advocacy Network (BCAN) to increase awareness about the signs, symptoms, diagnosis, treatment and need for a multidisciplinary approach to the care of patients with muscle-invasive bladder cancer (MIBC).</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>We developed a 32-question survey with input from physicians, nurses, patients and caregivers. The survey was posted on the BCAN website between August 2013 and September 2014 (Cohort A) and again between June 2023 and April 2024 (Cohort B). Questions focused on time from initial symptoms to diagnosis and treatment, proportion seeing a medical oncologist or radiation oncologist, treatments offered/received, and patient satisfaction with their treatment choices.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Overall, 337 self-selected patients mostly white males from the US or Canada, with at least an undergraduate education completed the survey. There were 243 patients in Cohort A and 94 patients in Cohort B. The median age (range) at diagnosis was 61 (31–93) in Cohort A and 63 (38–87) in Cohort B. The most common presenting symptom was hematuria. In Cohorts A and B, 35% vs 30% (<i>P</i> = 0.56) waited &gt;3 months to seek medical attention, and in 38% vs 43% (<i>P</i> = 0.76) it took &gt;3 months to obtain a diagnosis. Men were more likely than women to be diagnosed within 1–2 months in both cohorts (Cohort A: 68% vs 47%; <i>P</i> = 0.03, Cohort B: 70% vs 37%; <i>P</i> = 0.03). Preoperative consultation with a radiation oncologist and bladder-sparing use were infrequent. More patients in Cohort A (77%) felt they had enough time to make decisions compared to Cohort B (67%) (<i>P</i> = 0.004). Most patients were satisfied with their treatment choices.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>There are ongoing areas of unmet need in MIBC, including reducing time to definitive diagnosis and treatment, especially in women, and increasing multidisciplinary assessments prior to definitive surgery. Respondents were self-selected, had access to the BCAN website, and were highly educated, potentially limiting the generalizability of these results.</p>\n </section>\n </div>","PeriodicalId":8985,"journal":{"name":"BJU International","volume":"136 3","pages":"493-499"},"PeriodicalIF":4.4000,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BJU International","FirstCategoryId":"3","ListUrlMain":"https://bjui-journals.onlinelibrary.wiley.com/doi/10.1111/bju.16695","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives

To evaluate the impact of advocacy efforts by organisations such as the Bladder Cancer Advocacy Network (BCAN) to increase awareness about the signs, symptoms, diagnosis, treatment and need for a multidisciplinary approach to the care of patients with muscle-invasive bladder cancer (MIBC).

Materials and Methods

We developed a 32-question survey with input from physicians, nurses, patients and caregivers. The survey was posted on the BCAN website between August 2013 and September 2014 (Cohort A) and again between June 2023 and April 2024 (Cohort B). Questions focused on time from initial symptoms to diagnosis and treatment, proportion seeing a medical oncologist or radiation oncologist, treatments offered/received, and patient satisfaction with their treatment choices.

Results

Overall, 337 self-selected patients mostly white males from the US or Canada, with at least an undergraduate education completed the survey. There were 243 patients in Cohort A and 94 patients in Cohort B. The median age (range) at diagnosis was 61 (31–93) in Cohort A and 63 (38–87) in Cohort B. The most common presenting symptom was hematuria. In Cohorts A and B, 35% vs 30% (P = 0.56) waited >3 months to seek medical attention, and in 38% vs 43% (P = 0.76) it took >3 months to obtain a diagnosis. Men were more likely than women to be diagnosed within 1–2 months in both cohorts (Cohort A: 68% vs 47%; P = 0.03, Cohort B: 70% vs 37%; P = 0.03). Preoperative consultation with a radiation oncologist and bladder-sparing use were infrequent. More patients in Cohort A (77%) felt they had enough time to make decisions compared to Cohort B (67%) (P = 0.004). Most patients were satisfied with their treatment choices.

Conclusions

There are ongoing areas of unmet need in MIBC, including reducing time to definitive diagnosis and treatment, especially in women, and increasing multidisciplinary assessments prior to definitive surgery. Respondents were self-selected, had access to the BCAN website, and were highly educated, potentially limiting the generalizability of these results.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
了解患者对肌肉浸润性膀胱癌治疗的看法
评估膀胱癌倡导网络(BCAN)等组织的宣传工作的影响,以提高对肌肉浸润性膀胱癌(MIBC)患者的体征、症状、诊断、治疗和多学科方法护理需求的认识。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
BJU International
BJU International 医学-泌尿学与肾脏学
CiteScore
9.10
自引率
4.40%
发文量
262
审稿时长
1 months
期刊介绍: BJUI is one of the most highly respected medical journals in the world, with a truly international range of published papers and appeal. Every issue gives invaluable practical information in the form of original articles, reviews, comments, surgical education articles, and translational science articles in the field of urology. BJUI employs topical sections, and is in full colour, making it easier to browse or search for something specific.
期刊最新文献
Digital Uromonitor® outperforms quantitative polymerase chain reaction Uromonitor and cytology for non-muscle-invasive bladder cancer surveillance: results from the ‘External Validation of Uromonitor as a Biomarker for Optimization of NMIBC Management by the Club Urológico Español de Tratamiento Oncológico Group’ (EVALUATION-CUETO) study The 'Co-Qual': Real-time assessment of prostate biopsy core quality using fluorescence confocal microscopy. Reducing complexity in International Bladder Cancer Group intermediate-risk non-muscle-invasive bladder cancer stratification: a three-factor approach. Response to comment by Semwal et al. Comment on 'Prostate zonal impact of 5α-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer'.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1